NTLA - インテリア・セラピュ―ティクス (Intellia Therapeutics Inc.) インテリア・セラピュ―ティクス

 NTLAのチャート


 NTLAの企業情報

symbol NTLA
会社名 Intellia Therapeutics Inc (インテリア・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: In Vitro_In Vivo Diagnostic Substances  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 インテリア・セラピューティクス(Intellia Therapeutics Inc.)はゲノム編集会社である。同社はCRISPR/Cas9という生物学的ツールを利用した治療法の開発に従事する。CRISPR/Cas9ゲノム編集システムは2つの成分を含む。Cas9タンパク質は遺伝子のノックアウト・修復・挿入のための自然細胞修復プロセスを開始する分子ハサミのように働く。ガイドRNA配列はCas9を特定の標的デオキシリボ核酸(DNA)配列に認識し導く。同社のセンチネルインビボプログラムは、肝臓へのCRISPR/Cas9複合体の送達のための脂質ナノ粒子(LNP)の使用に焦点を当てる。同社の事業部であるeXtellia Therapeuticsは、免疫腫瘍学・自己免疫性疾患・炎症性疾患の分野におけるCRISPR / Cas9ゲノム編集の応用に従事する。同社の子会社はIntellia Securities Corpを含む。   インテリア・セラピュ―ティクスは米国のライフサイエンス企業。遺伝子改変技術に取り組み、ゲノム編集ツ―ルである「クリスパ―・キャス9(CRISPR/Cas9)」システムを利用し、トランスチレチン・アミロイド症やB型肝炎、アンチトリプシン欠乏症などの治療を可能にする。本社はマサチュ―セッツ州ケンブリッジ。   
本社所在地 40 Erie Street Suite 130 Cambridge MA 02139 USA
代表者氏名 Perry A. Karsen ペリーA.カーセン
代表者役職名 Independent Chairman of the Board
電話番号 +1 857-285-6200
設立年月日 41760
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数 195人
url www.intelliatx.com
nasdaq_url https://www.nasdaq.com/symbol/ntla
adr_tso
EBITDA EBITDA(百万ドル) -82.90700
終値(lastsale) 24.21
時価総額(marketcap) 1045887324.93
時価総額 時価総額(百万ドル) 958.62210
売上高 売上高(百万ドル) 29.13100
企業価値(EV) 企業価値(EV)(百万ドル) 653.08410
当期純利益 当期純利益(百万ドル) -82.89400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Intellia Therapeutics Inc revenues increased 25% to $15.1M. Net loss increased 54% to $43.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research_Development - Balancing value increase of 58% to $40.9M (expense) Stock-based Compensation in R&D increase of 64% to $5M (expense).

 NTLAのテクニカル分析


 NTLAのニュース

   Oppenheimer Stick to Their Hold Rating for Intellia Therapeutics By Investing.com  2021/05/27 16:05:12 Investing.com
Oppenheimer Stick to Their Hold Rating for Intellia Therapeutics
   Intellia Therapeutics Inc Shares Close the Day 10.1% Higher - Daily Wrap  2021/05/11 22:30:00 Kwhen Finance
Intellia Therapeutics Inc (NTLA) shares closed today 10.1% higher than it did at the end of yesterday. The stock is currently up 23.2% year-to-date, up 279.6% over the past 12 months, and up 186.6% over the past five years. Today, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 1.5%. Trading Activity Shares traded as high as $68.82 and as low as $56.47 this week.Shares closed 3e+1% below its 52-week high and 3e+2% above its 52-week low.Trading volume this week was 11.0% higher than the 10-day average and 18.9% higher than the 30-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 1.9. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, beats it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, beats it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -199.8% The company's stock price performance over the past 12 months beats the peer average by -3135.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Leerink Partners Stick to Their Buy Rating for Intellia Therapeutics By Investing.com  2021/03/02 14:48:20 Investing.com
Leerink Partners Stick to Their Buy Rating for Intellia Therapeutics
   Robert W. Baird Stick to Their Hold Rating for Intellia Therapeutics By Investing.com  2021/02/28 14:45:51 Investing.com
Robert W. Baird Stick to Their Hold Rating for Intellia Therapeutics
   FXNEWS24 |Vertex, Intellia Therapeutics: Gene Modifying Shares To Watch | UK Forex Reviews  2021/02/12 11:33:11 FXNews24
Vertex, Intellia Therapeutics: Gene Modifying Shares To Watch | UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News
   Intellia Therapeutics, Inc. (NASDAQ:NTLA) CEO Sells $1,552,255.72 in Stock  2021/02/12 11:27:09 Watchlist News
Intellia Therapeutics, Inc. (NASDAQ:NTLA) CEO John M. Leonard sold 22,942 shares of the firm’s stock in a transaction that occurred on Friday, February 5th. The shares were sold at an average price of $67.66, for a total value of $1,552,255.72. Following the sale, the chief executive officer now owns 654,803 shares of the company’s stock, […]
   Intellia Therapeutics, Inc. (NASDAQ:NTLA) EVP Sells $861,675.00 in Stock  2021/02/12 10:43:12 Watchlist News
Intellia Therapeutics, Inc. (NASDAQ:NTLA) EVP Jose E. Rivera sold 11,489 shares of the stock in a transaction that occurred on Tuesday, February 9th. The stock was sold at an average price of $75.00, for a total value of $861,675.00. Following the completion of the transaction, the executive vice president now directly owns 129,409 shares of […]
   FXNEWS24 |Vertex, Intellia Therapeutics: Gene Modifying Shares To Watch | UK Forex Reviews  2021/02/12 11:33:11 FXNews24
Vertex, Intellia Therapeutics: Gene Modifying Shares To Watch | UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News
   Intellia Therapeutics, Inc. (NASDAQ:NTLA) CEO Sells $1,552,255.72 in Stock  2021/02/12 11:27:09 Watchlist News
Intellia Therapeutics, Inc. (NASDAQ:NTLA) CEO John M. Leonard sold 22,942 shares of the firm’s stock in a transaction that occurred on Friday, February 5th. The shares were sold at an average price of $67.66, for a total value of $1,552,255.72. Following the sale, the chief executive officer now owns 654,803 shares of the company’s stock, […]
   Intellia Therapeutics, Inc. (NASDAQ:NTLA) EVP Sells $861,675.00 in Stock  2021/02/12 10:43:12 Watchlist News
Intellia Therapeutics, Inc. (NASDAQ:NTLA) EVP Jose E. Rivera sold 11,489 shares of the stock in a transaction that occurred on Tuesday, February 9th. The stock was sold at an average price of $75.00, for a total value of $861,675.00. Following the completion of the transaction, the executive vice president now directly owns 129,409 shares of […]
   John M. Leonard Sells 109,889 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) Stock  2021/02/05 09:24:43 Watchlist News
Intellia Therapeutics, Inc. (NASDAQ:NTLA) CEO John M. Leonard sold 109,889 shares of the firm’s stock in a transaction dated Monday, February 1st. The shares were sold at an average price of $64.00, for a total transaction of $7,032,896.00. Following the completion of the sale, the chief executive officer now owns 575,488 shares of the company’s […]
   Raymond James Stick to Their Buy Rating for Intellia Therapeutics By Investing.com  2021/01/08 16:51:48 Investing.com
Raymond James Stick to Their Buy Rating for Intellia Therapeutics

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 インテリア・セラピュ―ティクス NTLA Intellia Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)